Sr. Director - HCP Media at Eli Lilly and Company

Indianapolis, Indiana, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, HealthcareIndustries

Requirements

Expertise in HCP media strategy and investment, serving as the enterprise expert
Ability to define strategic vision, governance models, and innovation roadmaps for HCP media channels (SOA, EHR, endemic display, programmatic, point of care)
Strong partnership skills with medical, legal, regulatory, and data governance teams to ensure compliance, privacy, and transparency
Proficiency in data-driven insights for channel performance evaluation, targeting, measurement, and optimization
Experience leading cross-functional collaboration and influencing senior executives and brand teams
Skills in vendor, agency, and partner management, including performance standards and accountability
Capability to manage enterprise-level financial investments with fiscal discipline and compliance

Responsibilities

Define and lead the enterprise HCP media strategy, establishing frameworks for investment, targeting, measurement, and compliance
Build a unified media vision across professional channels (SOA e.g., Medscape, Doximity; EHR ecosystems; endemic display; programmatic; point of care) for consistency, scalability, and impact
Partner with medical, legal, regulatory, and data governance teams to uphold privacy, transparency, and compliance standards
Identify, prioritize, and manage investments shaping HCP engagement, education, and prescribing behavior
Develop and evolve integrated HCP media frameworks, optimizing for reach, efficiency, and clinical relevance
Oversee vendor and partnership strategies, establishing performance standards and accountability for innovation and impact
Evaluate channel performance through data-driven insights to ensure measurable engagement, trust, and value
Serve as enterprise expert and advisor to brand teams, executives, and cross-functional partners on HCP media strategy
Translate media data and market insights into actionable enterprise recommendations
Build organizational understanding of the HCP media ecosystem for customer-centric engagement
Oversee relationships with HCP media partners, agencies, and platforms, ensuring alignment with objectives and governance
Drive accountability through partnership reviews, innovation pilots, and measurement frameworks
Manage enterprise-level HCP media investments across platforms and brands
Implement transparent governance for fiscal discipline, compliance, and alignment with priorities
Safeguard HCP media practices to meet or exceed requirements

Skills

HCP Media Strategy

Programmatic Media

EHR Ecosystems

Endemic Display

Point of Care Media

Media Governance

Targeting

Measurement

Compliance

Data Governance

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free